Stifel Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $30

Benzinga Newsdesk www.benzinga.com Positive 59.0%

Neg 0% Neu 0% Pos 59%

Stifel analyst Paul Matteis initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $30.